Clinical limitations of static genome analysis and the bottleneck of phenotypic variability in Endometrial Cancer (EC). EC is a highly heterogeneous malignancy at both clinical and molecular levels. Although precision stratification efforts such as the TCGA classification have been introduced, clinicians repeatedly observe that tumors sharing identical variant call format (VCF) profiles and molecular subtypes exhibit widely divergent drug responses and can rapidly acquire acquired resistance to standard chemotherapy. This indicates the presence of dynamic survival‑regulatory mechanisms under therapeutic pressure that cannot be explained solely by static genomic alterations. The omission of these genetic factors and phenotypic plasticity constitutes a critical technical bottleneck that undermines prognostic scoring.

Triple‑epigenetic network analysis and causal evidence for adaptive reprogramming. In May, we launched an ultra‑high‑resolution multi‑omics framework that integrates DNA methylation, histone modifications, and non‑coding RNA (ncRNA) networks into a single statistical matrix. By tracking how epigenetic regulators remodel chromatin accessibility during drug‑induced transcriptional reprogramming, we pinpointed causal molecular links. We demonstrated biophysically that artificial reprogramming of key upstream epigenetic switches in metabolic and oncogenic pathways can reversibly and completely reverse acquired drug resistance.

Restoration of reversible cellular susceptibility using histone deacetylase inhibitors (HDACi). The therapeutic breakthrough lies in moving away from rigid DNA‑editing strategies toward a mathematically modeled combination therapy that exploits epigenomic reversibility. In preclinical models, administration of a specific HDAC inhibitor forced open closed chromatin, transiently relieving transcriptional repression. This epigenetic reshuffling reactivated sensitivity kinetics, rendering previously fully resistant EC cell lines highly responsive to cytotoxic and targeted agents.

Global standardization of next‑generation companion diagnostic (CDx) platforms based on epigenome profiling. The epigenetic engineering and multi‑omics tensor dataset generated herein have disruptive implications for global oncology R&D and digital precision diagnostics. By replacing static sequencing‑based resistance monitoring with a personalized epigenetic profiling and reversible adaptive drug‑switch simulation infrastructure, we established a scoring system that predicts resistance trajectories from multidimensional omics data. This serves as a master reference to filter post‑treatment false‑positive non‑response noise in clinical trials and to dramatically shorten IND approval timelines for next‑generation epigenetic‑targeted combination therapies worldwide.